In our previous studies, we demonstrated that pharmacological decrease of CIP2A, thereby increased PP2A activity and subsequent inactivation of the p-Akt signaling, inhibited proliferation and induced apoptosis in breast cancer cells [13, 14]. The gene discussed is AKT1; the disease is breast carcinoma.